{"id":"n_uhsbqowspqlbg244jqxq","seq":11084316,"kind":"article","title":"Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer","url":"https://www.2minutemedicine.com/durvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer","published":"2026-11-14T14:54:00Z","seen":"2026-11-14T14:54:00Z","lang":"en","source":{"id":"2minutemedicine.com","name":"2minutemedicine.com","domain":"2minutemedicine.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"authors":["2 Minute Medicine","Reviewed Marc Succi","MD (Harvard Medical School)"],"entities":[{"id":"Q19904005","name":"durvalumab","type":"other"},{"id":"Q19904068","name":"enfortumab vedotin","type":"other"}],"story":"st_gxlyph6yblx23rm3m2eq","category":"health","category_p":0.6,"sentiment":"neutral","tone":0.18,"political":0.12}